Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14642)	9/16/2000 8:47:26 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

CACAITO!!!! SHAME ON YOU!!!!! Are you saying NO medications have been approved under Subpart E that fall short of classic statistical significance??? Clinical benefit was shown!!!! REREAD THE THE SUBPART E GUIDELINES!!

To: Cacaito who wrote (14642)	9/16/2000 8:55:41 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

simple example: If drug A is able to disolve clots and disolving clots is clearly good to save a limb, then one could MAYBE considered just disolving the clots as a basis for approval... of drug A > simple example: If drug bpi is able to disolve clots and disolving clots is clearly good to save a limb, then one could MAYBE considered just disolving the clots as a basis for approval... of drug A (I believe bpi disoles clots) > simple example: If drug bpi is able to neutralize endotoxins and neutralizing endotoxins is clearly good to save a limb or a life, then one could MAYBE considered just neutralizing endotoxins as a basis for approval... of drug BPI (make sense to me, thanks Cacaito)